Biotech | October 01, 2021
Jubilant concludes pre-IND meeting of JB1-802 with U.S. FDA
The company plans to submit the IND application by the end of 2021
The company plans to submit the IND application by the end of 2021
The AI-infused solution enables radiologists by fast triaging abnormalities in X-ray, annotating and automatic report generation with significantly improved performance
The issue will consist of the issuance of fresh equity shares worth up to Rs 331.60 crore and an offer for sale (OFS) of Rs 500 crore by promoters and existing shareholders
A total of 707 district hospitals across all states and union territories participated in the performance assessment. The Health Management Information System (HMIS) data for the year 2017–18 has been used as a baseline for this exercise
Takeda to exclusively commercialize JR-141 outside the U.S. (except Japan and certain other Asia-Pacific countries) upon regulatory approval
If cleared, Merck's drug would be the first pill shown to treat Covid-19, a potentially major advance in efforts to fight the pandemic
The site's strategic location in the logistics hubs of the Auvergne Rhone-Alpes region is an advantage, along with the benefit of geographical proximity to Arrow's headquarters in Lyon
The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all
Fortis Memorial Research Institute is the only hospital in India and South Asia to acquire the machine
The global wellness market is valued at more than US $ 1.5 trillion, with annual growth of 5-10 per cent
Subscribe To Our Newsletter & Stay Updated
